Age: 42.0
Sex: F
Vaccine: COVID19, UNK, UNK
Symptoms: Arthralgia, COVID-19, Interchange of vaccine products, SARS-CoV-2 test, Therapeutic product effect decreased
Clinical narrative: Interchange of vaccine products; Wearing off effect; Drug effect decreased; COVID-19; Wrist pain; This spontaneous case was reported by a consumer and describes the occurrence of INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products), THERAPEUTIC RESPONSE SHORTENED (Wearing off effect), THERAPEUTIC PRODUCT EFFECT DECREASED (Drug effect decreased), COVID-19 (COVID-19) and ARTHRALGIA (Wrist pain) in a 42-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect products included non-company products ADALIMUMAB (HUMIRA) for Psoriatic arthritis and TOZINAMERAN for an unknown indication.    Previously administered products included for COVID-19 vaccination: PFIZER BIONTECH COVID-19 VACCINE(TOZINAMERAN) (Route: Intra-muscular Dose number: 1) on 01-Mar-2021 and PFIZER BIONTECH COVID-19 VACCINE(TOZINAMERAN) (Route: Intra-muscular Dose number: 2) in April 2021. Past adverse reactions to the above products included No adverse event with PFIZER BIONTECH COVID-19 VACCINE(TOZINAMERAN) and PFIZER BIONTECH COVID-19 VACCINE(TOZINAMERAN). Concurrent medical conditions included Psoriatic arthritis.   On 15-Jan-2022, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) at an unspecified dose and TOZINAMERAN (unknown route) at an unspecified dose. On an unknown date, the patient experienced INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products), THERAPEUTIC RESPONSE SHORTENED (Wearing off effect), THERAPEUTIC PRODUCT EFFECT DECREASED (Drug effect decreased), COVID-19 (COVID-19) and ARTHRALGIA (Wrist pain). At the time of the report, INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products), THERAPEUTIC RESPONSE SHORTENED (Wearing off effect) and THERAPEUTIC PRODUCT EFFECT DECREASED (Drug effect decreased) outcome was unknown, COVID-19 (COVID-19) had resolved and ARTHRALGIA (Wrist pain) was resolving.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, SARS-CoV-2 test: unknown unknown.         No concomitant medications were reported.  Event Neck pain, Back pain are subsumed under event Arthralgia.   on an unknown date, patient caught COVID after booster resolved. Pfizer BioNTech COVID-19 vaccine(tozinameran)and Moderna COVID-19 vaccine (elasomeran) were also considered suspect. No treatment medications were reported.  Company comment-This spontaneous case concerns a female patient aged 42 years with relevant medical history of Psoriatic arthropathy treated with co-suspect  Humira reported, who experienced the unexpected non serious AESI of Covid 19 on an unknown date after receiving the 3rd dose of mRNA-1273 vaccine in the covid 19 vaccination series.  She also experienced non serious events of Therapeutic response shortened, Drug Therapeutic product effect decreased and Arthralgia on unknown dates.Patient has received initial schedule of vaccination with co suspect TOZINAMERAN dose1 and 2. So interchange of vaccine products is noted. Outcome of the event covid-19 is resolved at the time of report. The current pandemic situation of COVID 19 may remain as confounder to the event covid-19, and relevant medical history remains a confounder to the event Arthralgia.  The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report. Event seriousness assessed per medical judgement.; Sender's Comments: This spontaneous case concerns a female patient aged 42 years with relevant medical history of Psoriatic arthropathy treated with co-suspect  Humira reported, who experienced the unexpected non serious AESI of Covid 19 on an unknown date after receiving the 3rd dose of mRNA-1273 vaccine in the covid 19 vaccination series.  She also experienced non serious events of Therapeutic response shortened, Drug Therapeutic product effect decreased and Arthralgia on unknown dates.Patient has received initial schedule of vaccination with co suspect TOZINAMERAN dose1 and 2. So interchange of vaccine products is noted. Outcome of the event covid-19 is resolved at the time of report. The current pandemic situation of COVID 19 may remain as confounder to the event covid-19, and relevant medical history remains a confounder to the event Arthralgia.  The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report. Event seriousness assessed per medical judgement.